Cibenzoline is a Vaughan-Williams class I anti-arrhythmic with properties intermediate between subclasses IA and IC which limit the incidence of proarrhythmic effects. These specific properties of the drug facilitate the prescription of cibenzoline in cardiology, particularly for the prevention of recurrent atrial arrhythmia: fibrillation, flutter, atrial tachycardia. This study demonstrates that cibenzoline is effective in these indications, since only 23% of the patients had relapsed after 6 months. This efficacy, combined with the good tolerance of the treatment, makes it possible to recommend the prescription of cibenzoline as a first-line treatment for the prevention of atrial arrhythmia. It represents an effective and safe option.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Age and Atrial Fibrillation Outcomes: Myth or Muzak, Scandinavian Lessons.
JACC Clin Electrophysiol
January 2025
Department of Cardiac Sciences, Libin Cardiovascular Institute, University of Calgary, Calgary, Alberta, Canada. Electronic address:
Recurrence of atrial fibrillation: Low dose colchicine and allopurinol.
Int J Cardiol
January 2025
Ertan Yetkin Professor of Cardiology, Şişli Kolan International Hospital, Istanbul, Türkiye. Electronic address:
The Southern Brazilian Registry of Atrial Fibrillation (SBR-AF Registry): Predictors of Atrial Arrhythmia Recurrence after First-Time Catheter Ablation.
Arq Bras Cardiol
January 2025
Serviço de Arritmia Cardíaca, Hospital SOS Cardio, Florianópolis, SC - Brasil.
Background: Treatment of atrial fibrillation (AF) with catheter ablation (CA) has evolved significantly. However, real-world data on long-term outcomes are limited, particularly in low- and middle-income countries.
Objective: This multicenter prospective cohort of consecutive patients aimed to evaluate the safety and efficacy of first-time CA for AF in Southern Brazil from 2009 to 2024.
Inflammation response post-radiofrequency ablation for atrial fibrillation: Implications for early atrial fibrillation recurrence.
Kardiol Pol
January 2025
Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
Cryptogenic stroke and patent foramen ovale: endeavoring for clarity.
Front Neurol
January 2025
School of International Medicine, Istanbul Medipol University, Istanbul, Türkiye.
This review aims to summarize current knowledge and highlight recent findings on the association between cryptogenic stroke (CS) and patent foramen ovale (PFO). By presenting sometimes conflicting data, the review underscores the necessity for further research to clarify the complex mechanisms behind PFO-related CS and optimize its management. Results from research identifies specific conditions and scores, such as the risk of paradoxical embolism (RoPE) score, that help assess the likelihood of PFO-related cryptogenic stroke and guide treatment decisions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!